Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz

  title={Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz},
  author={Fatemeh Dabaghzadeh and Hossein Khalili and Padideh Ghaeli and Simin Dashti-Khavidaki},
  journal={Expert Opinion on Pharmacotherapy},
  pages={2613 - 2624}
Introduction: More than 50% of HIV-positive patients experience neuropsychiatric adverse reactions following efavirenz therapy. Discontinuation of efavirenz due to its neuropsychiatric side effects has been reported in 2 – 13% of patients. Dizziness, headache, nightmares, abnormal dreams, mild cognitive difficulty, sleep disturbance (somnolence and insomnia), impaired concentration, depression, hallucination, delusion, paranoia, anxiety, agitation, aggressive behavior, mania, emotional… 
Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs
The evolving molecular mechanistic basis of NPAEs and abuse of efavirenz point to a complex and polymodal receptor pharmacology, and possible contributions of the mitochondrial-immune-inflammatory-redox cascade are explored in the context of the signaling mechanisms that appear to be involved.
RE: Severe mental illness at ART initiation is associated with worse retention in care among HIV‐infected Ugandan adults by JM Nachega et al. (2013), TMIH 18, pp 53–57
  • S. Kapoor
  • Psychology, Medicine
    Tropical medicine & international health : TM & IH
  • 2014
The general consensus is that efavirenz may alter cytokine levels that may contribute to the development of these psychiatric symptoms and the CD4 lymphocyte counts as well as the ‘viral load’ have a significant influence on the severity ofThese psychiatric effects.
Beneficial Effect of Cyproheptadine on Body Mass Index in Undernourished Children: A Randomized Controlled Trial
A significant higher body mass index was observed among CH-treated patients after 8 weeks intervention with cyproheptadine compared with the control group (P<0.041).
Associated factors of sleep quality in HIV-positive individuals
Depression, anxiety and physical morbidity were detected as main factors that affect sleep quality in the HIV-positive individuals.
Fatigue in Healthy and Diseased Individuals
Fatigue needs to be recognized as an important condition that is not only a symptom but may also be quantified and can be modified by various measures depending on the underlying cause.
Psychiatry and Neurology
LGBTQ individuals seeking mental or behavioral health care may present with similar complaints and stressors as their heterosexual counterparts, yet LGBT persons experience poorer mental health
Role of Cyproheptadine in Various Psychiatric Conditions


A Systematic Review of the Psychiatric Side-Effects of Efavirenz
High rates of neuropsychiatric side effects including vivid dreams, insomnia and mood changes in approximately 50% of patients who initiate efavirenz are identified, and there is no clear evidence of a broadly increased risk of suicide or dangerous behavior for patients taking efvirenz as part of their antiretroviral regimen.
Neuropsychiatric side effects of efavirenz therapy
This review describes neuropsychiatric symptoms provoked by EFV, differential-diagnostic procedures and treatment options, and provides pro's and con's for EFV use in clinical practice with respect to drug safety.
Long-Term Safety and Efficacy of NNRTI Within the Central Nervous System
No significant differences between both types of NNRTI treatment regimens were found with regard to duration of therapy and reasons for withdrawal, and neuropsychiatric side effects including the manifestation of depression, psychosis, insomnia, or other self-reported complaints.
Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence
Mild and clinically tolerable neuropsychiatric disorders may persist in patients after a mean of 2 years using an efavirenz-based approach and Interventions to enhance long-term adherence should be applied in clinical practice.
Stepped-Dose Versus Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events
This multicenter, randomized, double-blind, investigator-initiated clinical trial to verify whether stepped-dose efavirenz administration for the first 2 weeks of treatment decreases the incidence and severity of efvirenz-related NPAEs compared with the standard full dose.
Central Nervous System Adverse Effects with Efavirenz: Case Report and Review
A 47‐year‐old man with acquired immunodeficiency syndrome developed severe depression and suicidal ideation necessitating psychiatric hospitalization and antidepressant therapy necessitating mental health treatment.
Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz
Patients maintained on EFV showed a decrease in psychologic distress related to self‐image, depression, and anxiety, without any effect on quality of life.
Neurologic and Psychiatric Complications of Antiretroviral Agents
Treatment of Depression With Cyproheptadine
Cyproheptadine HCl may be useful in treating a subset of patients with major depression who have a suppressible dexamethasone suppression test and has lower scores on the Hamilton Depression Rating Scale during treatment with cyprohePTadine.
Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity
The results demonstrated that NVP and EFV significantly inhibited CK activity in cerebellum, hippocampus, striatum and cortex of mice, suggesting that the inhibition of brain CK activity by NVPand EFV may be associated with neurological adverse symptoms of these drugs.